Content
03/06/2024
Boston, MA USA
Sionna Therapeutics
completed $182 million Series C Round funding. Investors include
OrbiMed Advisors, Atlas Venture, Perceptive Advisors, RA Capital Management, TPG, Viking Global Investors.
About
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
